JP7229618B2 - エリスロポエチン産生能が亢進された線維芽細胞 - Google Patents

エリスロポエチン産生能が亢進された線維芽細胞 Download PDF

Info

Publication number
JP7229618B2
JP7229618B2 JP2022504446A JP2022504446A JP7229618B2 JP 7229618 B2 JP7229618 B2 JP 7229618B2 JP 2022504446 A JP2022504446 A JP 2022504446A JP 2022504446 A JP2022504446 A JP 2022504446A JP 7229618 B2 JP7229618 B2 JP 7229618B2
Authority
JP
Japan
Prior art keywords
fibroblasts
epo
kidney
cells
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504446A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021177387A1 (https=
JPWO2021177387A5 (https=
Inventor
貴紘 岩宮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metcela Inc
Original Assignee
Metcela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc filed Critical Metcela Inc
Publication of JPWO2021177387A1 publication Critical patent/JPWO2021177387A1/ja
Publication of JPWO2021177387A5 publication Critical patent/JPWO2021177387A5/ja
Priority to JP2023017770A priority Critical patent/JP2023053044A/ja
Application granted granted Critical
Publication of JP7229618B2 publication Critical patent/JP7229618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022504446A 2020-03-04 2021-03-04 エリスロポエチン産生能が亢進された線維芽細胞 Active JP7229618B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023017770A JP2023053044A (ja) 2020-03-04 2023-02-08 エリスロポエチン産生能が亢進された線維芽細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020036421 2020-03-04
JP2020036421 2020-03-04
PCT/JP2021/008325 WO2021177387A1 (ja) 2020-03-04 2021-03-04 エリスロポエチン産生能が亢進された線維芽細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017770A Division JP2023053044A (ja) 2020-03-04 2023-02-08 エリスロポエチン産生能が亢進された線維芽細胞

Publications (3)

Publication Number Publication Date
JPWO2021177387A1 JPWO2021177387A1 (https=) 2021-09-10
JPWO2021177387A5 JPWO2021177387A5 (https=) 2022-12-01
JP7229618B2 true JP7229618B2 (ja) 2023-02-28

Family

ID=77614075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504446A Active JP7229618B2 (ja) 2020-03-04 2021-03-04 エリスロポエチン産生能が亢進された線維芽細胞
JP2023017770A Pending JP2023053044A (ja) 2020-03-04 2023-02-08 エリスロポエチン産生能が亢進された線維芽細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023017770A Pending JP2023053044A (ja) 2020-03-04 2023-02-08 エリスロポエチン産生能が亢進された線維芽細胞

Country Status (9)

Country Link
US (1) US20220411761A1 (https=)
EP (1) EP4116412A4 (https=)
JP (2) JP7229618B2 (https=)
KR (1) KR20220148184A (https=)
CN (1) CN115210361B (https=)
AU (1) AU2021230209B2 (https=)
CA (1) CA3174551A1 (https=)
IL (1) IL296125A (https=)
WO (1) WO2021177387A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023037868A1 (https=) * 2021-09-08 2023-03-16
WO2025135526A1 (ko) * 2023-12-19 2025-06-26 재단법인대구경북과학기술원 피부 또는 모발의 멜라닌 색소 조절용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516820A (ja) 2000-08-25 2004-06-10 キュラジェン コーポレイション 新規タンパク質およびそれらのタンパク質をコードする核酸
US20050064443A1 (en) 1997-04-08 2005-03-24 Usa As Represented By The Administrator, National Aeronautics & Space Administration Production of functional proteins: balance of shear stress and gravity
JP2012508691A (ja) 2008-11-12 2012-04-12 テンジオン， インク． 単離した腎細胞およびその使用
JP2013528375A (ja) 2010-05-12 2013-07-11 テンジオン， インク． 生理活性腎臓細胞
JP2013174897A (ja) 2008-04-22 2013-09-05 Canon Inc 制御装置
WO2016006262A1 (ja) 2014-07-11 2016-01-14 貴紘 岩宮 心臓細胞培養材料
WO2018155651A1 (ja) 2017-02-24 2018-08-30 株式会社メトセラ 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
CA3110831A1 (en) * 2018-08-29 2020-03-05 Metcela Inc. Method for producing fibroblast, and g-csf-positive fibroblast mass

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064443A1 (en) 1997-04-08 2005-03-24 Usa As Represented By The Administrator, National Aeronautics & Space Administration Production of functional proteins: balance of shear stress and gravity
JP2004516820A (ja) 2000-08-25 2004-06-10 キュラジェン コーポレイション 新規タンパク質およびそれらのタンパク質をコードする核酸
JP2013174897A (ja) 2008-04-22 2013-09-05 Canon Inc 制御装置
JP2012508691A (ja) 2008-11-12 2012-04-12 テンジオン， インク． 単離した腎細胞およびその使用
JP2013528375A (ja) 2010-05-12 2013-07-11 テンジオン， インク． 生理活性腎臓細胞
WO2016006262A1 (ja) 2014-07-11 2016-01-14 貴紘 岩宮 心臓細胞培養材料
WO2018155651A1 (ja) 2017-02-24 2018-08-30 株式会社メトセラ 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Invest. Ophthalomol. Vis. Sci., 2005, Vol.46, No.12, pp.4512-4518

Also Published As

Publication number Publication date
JPWO2021177387A1 (https=) 2021-09-10
JP2023053044A (ja) 2023-04-12
EP4116412A4 (en) 2024-04-03
CN115210361B (zh) 2024-12-10
AU2021230209B2 (en) 2025-01-30
EP4116412A1 (en) 2023-01-11
KR20220148184A (ko) 2022-11-04
IL296125A (en) 2022-11-01
CN115210361A (zh) 2022-10-18
AU2021230209A1 (en) 2022-09-29
WO2021177387A1 (ja) 2021-09-10
US20220411761A1 (en) 2022-12-29
CA3174551A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
JP6682090B2 (ja) 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法
CN102911989B (zh) 脐带血干细胞增殖和生长因子产生的锂刺激
JP6883904B2 (ja) 線維芽細胞の製造方法及びｇ−ｃｓｆ陽性線維芽細胞集団
CN110898078B (zh) 一种间充质干细胞分泌因子的制备及应用
WO2015137419A1 (ja) 間葉系幹細胞の賦活化剤、賦活化された間葉系幹細胞およびその製造方法
JP2023053044A (ja) エリスロポエチン産生能が亢進された線維芽細胞
KR20080042761A (ko) 렙틴을 이용한 줄기세포 증식방법
TWI589698B (zh) 間質幹細胞、其純株化擴張之方法、其分離方法及其應用
Katahira et al. Protective effects of conditioned media of immortalized stem cells from human exfoliated deciduous teeth on pressure ulcer formation
JP6766082B2 (ja) 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途
JP7546193B2 (ja) 細胞群及びその取得方法
JP2018530992A6 (ja) 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途
US20240316113A1 (en) Fibroblast-containing pharmaceutical composition for treating kidney disease
JP6706836B2 (ja) 単核球培養用無血清培地
JP2022017977A (ja) 細胞、組成物及び治療用組成物
CN120857934A (zh) 一种用于预防和/或治疗与脑血流减少相关的疾病或状态的药物
Deng et al. Fundamental Concepts and Features of Proliferation, Mesenchymal Stem Cells: Differentiation, Migration and Immunomodulatory Characteristics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220914

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220914

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7229618

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250